About Aclaris Therapeutics (NASDAQ:ACRS)
Aclaris Therapeutics, Inc. is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer. The Company's drug discovery platform KINect technology is a kinase-focused drug discovery engine utilizing computational chemistry to integrate proprietary compound collections and highly experienced biologists and medicinal chemists to identify and advance potential candidates into preclinical and clinical development.
Industry, Sector and Symbol
Industry Bio Therapeutic Drugs
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Book Value$7.92 per share
Price / Book2.92
Return on Equity-30.76%
Return on Assets-29.25%
Frequently Asked Questions for Aclaris Therapeutics (NASDAQ:ACRS)
What is Aclaris Therapeutics' stock symbol?
Aclaris Therapeutics trades on the NASDAQ under the ticker symbol "ACRS."
How were Aclaris Therapeutics' earnings last quarter?
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) issued its quarterly earnings results on Tuesday, November, 7th. The biotechnology company reported ($0.63) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.86) by $0.23. The biotechnology company earned $0.68 million during the quarter, compared to analysts' expectations of $2 million. View Aclaris Therapeutics' Earnings History.
Where is Aclaris Therapeutics' stock going? Where will Aclaris Therapeutics' stock price be in 2017?
5 equities research analysts have issued twelve-month price objectives for Aclaris Therapeutics' shares. Their predictions range from $36.00 to $50.00. On average, they anticipate Aclaris Therapeutics' stock price to reach $41.25 in the next year. View Analyst Ratings for Aclaris Therapeutics.
What are Wall Street analysts saying about Aclaris Therapeutics stock?
Here are some recent quotes from research analysts about Aclaris Therapeutics stock:
- 1. Cantor Fitzgerald analysts commented, "Positives from the quarter: 1) ACRS acquired Confluence Life Sciences (private) for $20MM upfront, consisting of $10MM in cash and $10MM in stock, 2) ACRS submitted a MAA for A-101 40% for the treatment of SK in Sweden, which is to serve as the reference member state, 3) ACRS appointed Andrew Schiff to its Board of Directors, 4) The USPTO issued two patents covering JAK inhibitors for treating hair loss disorders, covering a total of 32 claims out to November 2031, 5) ACRS published data from its Phase 2 trial of A-101 topical solution (40% and 32.5%) for the treatment of SK in the journal Dermatologic Surgery, 6) As of 9/30/17, ACRS had $227.8MM of cash, enough to fund operations through 2H19, 7) PDUFA for A-101 to treat SK is 12/24/17, 8) Enrollment of two Phase 2 trials of A-101 45% Topical Solution for the treatment of common warts is complete, ACRS expects data 1H18, 9) In October ACRS initiated a Phase 2 clinical trial of ATI-50002 topical for AA. This trial will evaluate PK, PD and safety and data is expected 1Q18. 10) ACRS initiated a Phase 2 open-label clinical trial of ATI-50002 Topical for the treatment of AA. This trial will evaluate the regrowth of eyebrows, and data is also expected to be available in 1H18. And 11) ACRS plans to initiate a Phase 2 dose-ranging trial of ATI-50002 Topical for the treatment of AA next week. Data is expected by year end 2018." (11/7/2017)
- 2. According to Zacks Investment Research, "Aclaris Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to met needs in dermatology. Its drug candidate consists of A-101, a high-concentration hydrogen peroxide topical solution which is being developed as a prescription treatment for seborrheic keratosis a common non-malignant skin tumor and A-102, a proprietary topical gel dosage form of hydrogen peroxide for the treatment of SK and common warts which are in different clinical trial. Aclaris Therapeutics, Inc. is headquartered in Malvern, Pennsylvania. " (10/11/2017)
- 3. Jefferies Group LLC analysts commented, "ACRS reported a narrower Q4 loss of $11.5M (vs $14.5M JEF) due to lower than projected R&D spend post the SK Ph3 trials. Attention now turns to three new clinical trials (A-101 Phase 2b in common warts and two JAK Ph 2s in alopecia areata) as we wait for an FDA decision on A-101 in SKs in early '18. We continue to forecast peak sales approaching $500M for the drug/device combo and think ACRS fits our M&A thesis." (3/16/2017)
- 4. Guggenheim analysts commented, "We are raising our PT from $35 to $40 post 4Q16. We arrive at our PT by using a DCF analysis. Post the quarter, we continue to believe that upwards earnings revisions to levels not yet reflected in sell-side expectations should drive ACRS shares higher. We believe upwards consensus earnings revisions could come from: 1) Faster than expected uptake and higher than expected peak sales of A-101 for SK; 2) Commercialization of A-101 for common warts; and, 3) Free call options on ATI-50001, ATI-50002, and other early stage pipeline opportunities." (3/15/2017)
Who are some of Aclaris Therapeutics' key competitors?
Some companies that are related to Aclaris Therapeutics include Ascendis Pharma A/S (ASND), MyoKardia (MYOK), Sangamo Therapeutics (SGMO), Clinigen Group PLC (CLIN), Radius Health (RDUS), Dynavax Technologies Corporation (DVAX), Ignyta (RXDX), Athenex (ATNX), Neuroderm Ltd (NDRM), Xencor (XNCR), Lexicon Pharmaceuticals (LXRX), Dermira (DERM), Acorda Therapeutics (ACOR), REGENXBIO (RGNX), Amarin Corporation PLC (AMRN), Epizyme (EPZM), Flexion Therapeutics (FLXN) and Omeros Corporation (OMER).
Who are Aclaris Therapeutics' key executives?
Aclaris Therapeutics' management team includes the folowing people:
- Stephen A. Tullman, Chairman of the Board (Age 51)
- Neal Walker, President, Chief Executive Officer, Director (Age 47)
- Frank Ruffo CPA, Chief Financial Officer, Secretary (Age 51)
- Christopher Powala, Chief Operating Officer (Age 57)
- Stuart D. Shanler M.D., Chief Scientific Officer (Age 56)
- Kamil Ali-Jackson J.D., Chief Legal Officer (Age 58)
- Richard A. Bierly, Independent Director (Age 61)
- William D. Humphries, Independent Director (Age 50)
- Anand Mehra M.D., Independent Director (Age 41)
- Andrew Kenneth William Powell, Independent Director (Age 59)
Who owns Aclaris Therapeutics stock?
Aclaris Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include
VIVO VENTURES VII, LLC
VIVO VENTURES VII, LLC
(5.50%), Eagle Asset Management Inc. (4.48%), Westfield Capital Management Co. LP (3.54%), Point72 Asset Management L.P. (2.89%) and Alyeska Investment Group L.P. (1.52%). Company insiders that own Aclaris Therapeutics stock include Anand Mehra, Andrew N Schiff, Kamil Ali-Jackson, Ra Capital Management, Llc and Ventures Fund Vii LP Vivo. View Institutional Ownership Trends for Aclaris Therapeutics.
Who sold Aclaris Therapeutics stock? Who is selling Aclaris Therapeutics stock?
Aclaris Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Westfield Capital Management Co. LP, Sei Investments Co. and New York State Common Retirement Fund. Company insiders that have sold Aclaris Therapeutics company stock in the last year include Anand Mehra and Ventures Fund Vii LP Vivo. View Insider Buying and Selling for Aclaris Therapeutics.
Who bought Aclaris Therapeutics stock? Who is buying Aclaris Therapeutics stock?
Aclaris Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Alyeska Investment Group L.P., Citadel Advisors LLC, Highbridge Capital Management LLC, Schwab Charles Investment Management Inc., Point72 Asset Management L.P., Cadence Capital Management LLC, Eagle Asset Management Inc. and Bank of New York Mellon Corp. Company insiders that have bought Aclaris Therapeutics stock in the last two years include Andrew N Schiff and Ra Capital Management, Llc. View Insider Buying and Selling for Aclaris Therapeutics.
How do I buy Aclaris Therapeutics stock?
Shares of Aclaris Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aclaris Therapeutics' stock price today?
One share of Aclaris Therapeutics stock can currently be purchased for approximately $23.12.
How big of a company is Aclaris Therapeutics?
Aclaris Therapeutics has a market capitalization of $699.64 million. The biotechnology company earns $-48,070,000.00 in net income (profit) each year or ($2.16) on an earnings per share basis. Aclaris Therapeutics employs 31 workers across the globe.
How can I contact Aclaris Therapeutics?
Aclaris Therapeutics' mailing address is 101 LINDENWOOD DRIVE SUITE 400, MALVERN PA, 19355. The biotechnology company can be reached via phone at 484-324-7933 or via email at [email protected]
MarketBeat Community Rating for Aclaris Therapeutics (ACRS)MarketBeat's community ratings are surveys of what our community members think about Aclaris Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for Aclaris Therapeutics (NASDAQ:ACRS) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 0 Hold Ratings, 5 Buy Ratings, 0 Strong Buy Ratings|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||$41.25 (78.42% upside)|
Consensus Price Target History for Aclaris Therapeutics (NASDAQ:ACRS)
Analysts' Ratings History for Aclaris Therapeutics (NASDAQ:ACRS)
(Data available from 11/23/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|11/7/2017||Cantor Fitzgerald||Reiterated Rating||Buy||$50.00||N/A|
|9/8/2017||JMP Securities||Reiterated Rating||Outperform||$39.00||High|
|7/31/2017||Jefferies Group LLC||Reiterated Rating||Buy||$36.00||High|
|11/29/2016||Leerink Swann||Initiated Coverage||Outperform||N/A|
|3/16/2016||Citigroup Inc.||Lower Price Target||Buy||$34.00 -> $29.00||N/A|
Earnings History and Estimates Chart for Aclaris Therapeutics (NASDAQ:ACRS)
Earnings History by Quarter for Aclaris Therapeutics (NASDAQ ACRS)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/7/2017||Q3 2017||($0.86)||($0.63)||$2.00 million||$0.68 million||View||N/A|
Earnings Estimates for Aclaris Therapeutics (NASDAQ:ACRS)
2017 EPS Consensus Estimate: ($3.02)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Aclaris Therapeutics (NASDAQ:ACRS)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Aclaris Therapeutics (NASDAQ ACRS)
Insider Ownership Percentage: 16.30%
Institutional Ownership Percentage: 85.22%
Insider Trades by Quarter for Aclaris Therapeutics (NASDAQ ACRS)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|8/16/2017||Andrew N Schiff||Director||Buy||108,601||$23.02||$2,499,995.02|| |
|3/2/2017||Ventures Fund Vii L.P. Vivo||Major Shareholder||Sell||425,000||$30.82||$13,098,500.00|| |
|1/10/2017||Anand Mehra||Director||Sell||750,000||$28.25||$21,187,500.00|| |
|11/18/2016||Ventures Fund Vii L.P. Vivo||Major Shareholder||Sell||907,828||$23.03||$20,907,278.84|| |
|10/26/2016||Kamil Ali-Jackson||Insider||Sell||3,912||$21.83||$85,398.96|| |
|9/28/2016||Kamil Ali-Jackson||Insider||Sell||1,841||$24.66||$45,399.06|| |
|9/16/2016||Ra Capital Management, Llc||Major Shareholder||Sell||525,550||$24.19||$12,713,054.50|| |
|8/26/2016||Kamil Ali-Jackson||Insider||Sell||3,738||$20.35||$76,068.30|| |
|2/23/2016||Ra Capital Management, Llc||Major Shareholder||Buy||39,726||$17.15||$681,300.90|| |
|1/20/2016||Ra Capital Management, Llc||Major Shareholder||Buy||7,803||$19.87||$155,045.61|| |
|1/13/2016||Ra Capital Management, Llc||Major Shareholder||Buy||15,637||$19.10||$298,666.70|| |
|10/29/2015||Ra Capital Management, Llc||Major Shareholder||Buy||244,200||$14.00||$3,418,800.00|| |
|10/22/2015||Ra Capital Management, Llc||Major Shareholder||Buy||5,410||$14.03||$75,902.30|| |
|10/21/2015||Ra Capital Management, Llc||Major Shareholder||Buy||34,999||$14.89||$521,135.11|| |
|10/14/2015||Ra Capital Management, Llc||Major Shareholder||Buy||42,813||$14.06||$601,950.78|| |
|10/13/2015||Albert Cha||Director||Buy||454,545||$11.00||$4,999,995.00|| |
|10/13/2015||Fmr Llc||Insider||Buy||335,455||$11.00||$3,690,005.00|| |
|10/13/2015||Sofinnova Venture Partners Vii||Major Shareholder||Buy||409,090||$11.00||$4,499,990.00|| |
|10/8/2015||Ra Capital Management, Llc||Major Shareholder||Buy||2,237,130||$10.86||$24,295,231.80|| |
|10/7/2015||Vivo Ventures Vii, Llc||Major Shareholder||Buy||13,352||$11.00||$146,872.00|| |
Latest Headlines for Aclaris Therapeutics (NASDAQ ACRS)
|Financial Analysis: Aclaris Therapeutics (ACRS) versus Its Rivals|
www.americanbankingnews.com - November 18 at 9:14 AM
|Zacks: Analysts Expect Aclaris Therapeutics, Inc. (ACRS) Will Announce Quarterly Sales of $800,000.00|
www.americanbankingnews.com - November 15 at 6:20 AM
|-$0.90 EPS Expected for Aclaris Therapeutics, Inc. (ACRS) This Quarter|
www.americanbankingnews.com - November 13 at 2:37 PM
|Brokers Issue Forecasts for Aclaris Therapeutics, Inc.'s FY2017 Earnings (ACRS)|
www.americanbankingnews.com - November 10 at 8:48 AM
|FY2017 Earnings Forecast for Aclaris Therapeutics, Inc. (ACRS) Issued By Jefferies Group|
www.americanbankingnews.com - November 10 at 8:38 AM
|Aclaris Therapeutics Mourns the Passing of Board Member Richard A. Bierly|
finance.yahoo.com - November 9 at 4:23 PM
|Leerink Swann Comments on Aclaris Therapeutics, Inc.'s FY2017 Earnings (ACRS)|
www.americanbankingnews.com - November 9 at 8:45 AM
|Aclaris Therapeutics, Inc. (ACRS) Issues Quarterly Earnings Results|
www.americanbankingnews.com - November 8 at 3:02 PM
|Oversold Conditions For Aclaris Therapeutics (ACRS)|
www.thestreet.com - November 7 at 9:57 PM
|Edited Transcript of ACRS earnings conference call or presentation 7-Nov-17 1:00pm GMT|
finance.yahoo.com - November 7 at 9:57 PM
|Aclaris Therapeutics Reports Third Quarter 2017 Financial Results|
finance.yahoo.com - November 7 at 4:56 PM
|Aclaris Therapeutics, Inc. (ACRS) Stock Rating Reaffirmed by Cantor Fitzgerald|
www.americanbankingnews.com - November 7 at 12:08 PM
|Aclaris Therapeutics, Inc. (ACRS) Given Consensus Rating of "Buy" by Analysts|
www.americanbankingnews.com - November 5 at 4:02 PM
|Aclaris Therapeutics to Attend Upcoming Investor Conferences|
finance.yahoo.com - November 3 at 10:18 AM
|Aclaris Therapeutics (ACRS) and The Competition Head-To-Head Analysis|
www.americanbankingnews.com - October 26 at 7:58 AM
|Aclaris Therapeutics, Inc. (ACRS) Set to Announce Earnings on Wednesday|
www.americanbankingnews.com - October 25 at 6:28 AM
|Aclaris Therapeutics, Inc. (ACRS) Rating Lowered to Hold at Zacks Investment Research|
www.americanbankingnews.com - October 11 at 5:20 PM
|Aclaris Therapeutics, Inc. (ACRS) Receives Consensus Rating of "Buy" from Analysts|
www.americanbankingnews.com - October 11 at 4:44 PM
|Aclaris Therapeutics, Inc. (ACRS) Stock Rating Upgraded by Zacks Investment Research|
www.americanbankingnews.com - October 10 at 8:56 PM
|Aclaris Therapeutics, Inc. (ACRS) PT Set at $50.00 by Cantor Fitzgerald|
www.americanbankingnews.com - October 5 at 9:30 PM
|Aclaris Therapeutics (ACRS) and Arrowhead Pharmaceuticals (ARWR) Critical Review|
www.americanbankingnews.com - October 2 at 12:22 PM
|Cantor Fitzgerald Reaffirms Buy Rating for Aclaris Therapeutics, Inc. (ACRS)|
www.americanbankingnews.com - September 26 at 5:38 PM
|Aclaris Therapeutics to Host R&D and Investor Event on October 4, 2017 in New York|
finance.yahoo.com - September 20 at 3:22 PM
|Publication in Dermatologic Surgery Highlights Dose-related Efficacy|
globenewswire.com - September 19 at 8:32 PM
|Aclaris Therapeutics Announces Publication of Data from Phase 2 Clinical Trial of A-101 Topical Solution for Treatment of Facial Seborrheic Keratosis|
finance.yahoo.com - September 19 at 3:28 PM
|Aclaris Therapeutics' (ACRS) Buy Rating Reiterated at Cantor Fitzgerald|
www.americanbankingnews.com - September 18 at 6:26 PM
|Aclaris Therapeutics, Inc. (ACRS) Given Consensus Rating of "Hold" by Brokerages|
www.americanbankingnews.com - September 16 at 4:34 PM
|JMP Securities Reiterates "Outperform" Rating for Aclaris Therapeutics, Inc. (ACRS)|
www.americanbankingnews.com - September 9 at 10:36 AM
|Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)|
finance.yahoo.com - September 7 at 8:23 PM
|Aclaris Therapeutics (ACRS) Granted Two U.S. Patents Covering JAK Inhibitors for Treating Hair Loss Disorders|
www.streetinsider.com - September 5 at 3:42 PM
|Aclaris Therapeutics Announces Issuance of Two U.S. Patents Covering JAK Inhibitors for Treating Hair Loss Disorders|
finance.yahoo.com - September 5 at 3:42 PM
|Aclaris Therapeutics, Inc. (ACRS) Given Consensus Rating of "Buy" by Brokerages|
www.americanbankingnews.com - August 22 at 4:36 PM
|Aclaris Therapeutics, Inc. (ACRS) Director Andrew N. Schiff Acquires 108,601 Shares|
www.americanbankingnews.com - August 16 at 7:39 PM
|Aclaris Therapeutics (ACRS) Prices 3.26M Share Offering at $23.02/Sh|
www.streetinsider.com - August 11 at 8:53 PM
|Q3 2017 EPS Estimates for Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Lifted by William Blair|
www.americanbankingnews.com - August 11 at 10:45 AM
|Research Analysts Set Expectations for Aclaris Therapeutics, Inc.'s Q3 2017 Earnings (ACRS)|
www.americanbankingnews.com - August 11 at 10:14 AM
|Q3 2017 Earnings Estimate for Aclaris Therapeutics, Inc. Issued By Leerink Swann (ACRS)|
www.americanbankingnews.com - August 11 at 10:14 AM
|FY2021 EPS Estimates for Aclaris Therapeutics, Inc. (ACRS) Reduced by Leerink Swann|
www.americanbankingnews.com - August 10 at 2:20 PM
|William Blair Weighs in on Aclaris Therapeutics, Inc.'s FY2020 Earnings (NASDAQ:ACRS)|
www.americanbankingnews.com - August 10 at 1:52 PM
| Brokerages Expect Aclaris Therapeutics, Inc. (ACRS) to Post -$0.91 EPS|
www.americanbankingnews.com - August 10 at 12:30 PM
|Aclaris Announces Proposed Public Offering of Common Stock|
finance.yahoo.com - August 9 at 8:44 PM
|Aclaris Therapeutics, Inc. (ACRS) Issues Earnings Results, Beats Estimates By $0.12 EPS|
www.americanbankingnews.com - August 9 at 4:34 PM
|Aclaris Announces Appointment of Andrew Schiff to Board of Directors|
finance.yahoo.com - August 9 at 3:43 PM
|Aclaris Therapeutics, Inc. (ACRS) Given a $50.00 Price Target by Cantor Fitzgerald Analysts|
www.americanbankingnews.com - August 9 at 1:32 PM
|Edited Transcript of ACRS earnings conference call or presentation 8-Aug-17 12:30pm GMT|
finance.yahoo.com - August 9 at 1:30 AM
|Houston VC-funded startup acquired in deal valued at $100 million|
www.bizjournals.com - August 8 at 8:28 PM
|Aclaris Therapeutics (ACRS) Acquires Confluence Life Sciences for $10M Cash, 350K Shares|
www.streetinsider.com - August 8 at 8:28 PM
|[$$] Aclaris Therapeutics Buys Confluence Life Sciences in $100 Million Deal|
finance.yahoo.com - August 8 at 8:28 PM
|Aclaris Therapeutics Reports Second Quarter 2017 Financial Results|
finance.yahoo.com - August 8 at 3:25 PM
|Aclaris reports 2Q loss|
finance.yahoo.com - August 8 at 3:25 PM
Aclaris Therapeutics (NASDAQ ACRS) Chart for Thursday, November, 23, 2017